Shots:

• Otsuka and Click have reported the initiation of the Mirai study which is a fully remote clinical trial to investigate the effectiveness of digital therapeutics in reducing depressive symptoms in adults diagnosed with MDD who are on antidepressant monotherapy. The study will enroll ~540 patients globally
• The trial will run fully remotely utilizing the Verily Project Baseline platform- a first-of-its-kind trial design for MDD. Participation will be of 10wks. and efficacy will be evaluated as a change from baseline in the MADRS total score
• The companies’ collaboration with Verily enables the trial to proceed efficiently and safely during the pandemic

 ­ Ref: Businesswire | Image: Contract Pharma